Abstract
Metals are a group of elements which are ubiquitous in modern life. They are used in the fields of cosmetics, water purification, medicine, paint, food products, pesticides, and almost innumerable others. As the use of metals has increased in recent decades, so has human exposure to these elements. Metals such as mercury, lead, arsenic, nickel, and others have been implicated in negatively affecting human homeostasis by causing chronic inflammatory diseases, among other serious conditions. Both acute and chronic metal toxicity in vital organs could arise from local or systemic exposure to numerous metals. Although some metals have health benefits, overaccumulation of metals in body tissues can result in deleterious, toxic effects. Most exposure to metals occurs via cutaneous, inhalation, or oral routes. At the highest risk of negative effects of exposure are pregnant women and children. To ameliorate or prevent the toxic effects of metals, chelating agents and barrier creams are used widely in medical practice today. In this chapter, we will discuss preventing metal toxicity from overexposure via chelation therapy and skin barrier creams.
This is a preview of subscription content, log in via an institution.
References
Tchounwou PB, Yedjou CG, Patlolla AK, Sutton DJ. Heavy metals toxicity and the environment. EXS. 2012;101:133–64.
Jarup L. Hazards of heavy metal contamination. Br Med Bull. 2003;68:167–82.
Vahter M, Berglund M, As kesson A, LideHn C. Metals and Women’s health. Environ Res Sect A. 2002;88:145–55.
Gardner RM, Kippler M, Tofail F, Bottai M, Hamadani J, Grander M, Nermell B, Palm B, Rasmussen KM, Vahter M. Environmental exposure to metals and children’s growth to age 5 years: a prospective cohort study. Am J Epidemiol. 2013;177:1356–67.
Bazzicalupi C, Bianchi A, Giorgi C, Clares MP, García-Espana E. Addressing selectivity criteria in binding equilibria. Coord Chem Rev. 2012;256:13–27.
Pearson RG. Chemical hardness and density functional theory. J Chem Sci. 2005;117:369–77.
Hancock RD, Martell AE. Ligand design for the selective complexation of metal ions in aqueous solution. Chem Rev. 1989;89:1875–914.
Crisponi G, Nurchi VM, Crespo-Alonso M, Toso L. Chelating agents for metal intoxication. Curr Med Chem. 2012;19:2794–815.
Grady RW, Berdoukas VA, Rachmilewitz EA, Galanello R, Borgna-Pignatti C, Giardina PJ. Optimizing chelation therapy: combining deferiprone and desferrioxamine. Blood. 1999;96(Suppl 1):604a.
Klaassen CD. Heavy metals and heavy metal antagonists. In: Goodman L, Gilman A, editors. The pharmacological basis of therapeutics. New York, NY: McGraw Hill, Medical Publishing Division; 2006. p. 1825–72.
Andersen O. Principles and recent developments in chelation treatment of metal intoxication. Chem Rev. 1999;99:2683–710.
DRUGDEX. Drug evaluation. In: Thomson MICROMEDEX Healthcare Series (Monograph on CD-ROM); 2004. p. 122.
Llobet JM, Domingo JL, Corbella J. Comparison of the effectiveness of several chelators after single administration on the toxicity, excretion and distribution of cobalt. Arch Toxicol. 1986;58:278–81.
Llobet JM, Domingo JL, Corbella J. Antidotes for zinc intoxication in mice. Arch Toxicol. 1988;61:321–3.
Radiation Emergency Assistance Center, Training Site (REAC/TS). Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate). Oak Ridge, TN: Oak Ridge Institute for Science and Education; 2002.
Spoor NL. The use of EDTA and DTPA for accelerating the removal of deposited transuranic elements from human. Didcot: Harwell; 1977.
Jech JJ, Andersen BV, Heid KR. Interpretation of human urinary excretion of plutonium for cases treated with DTPA. Health Phys. 1972;22:787–92.
Bulman RA, Griffin RJ, Russell AT. An examination of some complexing agents for ability to remove intracellularly deposited plutonium. Health Phys. 1979;37:729–34.
Stradling GN, Stather JW, Sumner SA, Moody JC, Strong JC. Decorporation of inhaled americium-241 dioxide and nitrate from hamsters using ZnDTPA and Puchel. Health Phys. 1984;46:1296–300.
Volf V, Peter E. DTPA is superior to its lipophilic derivative Puchel in removing 234Th, 238,239Pu and 241Am from Chinese hamsters and rats. Health Phys. 1984;46:422–6.
Stather JW, Stradling GN, Smith H, Payne S, James AC, Strong JC, Ham S, Sumner S, Bulman RA, Hodgson A, Towndrow C, Ellender M. Decorporation of 238PuO2 from the hamster by inhalation of chelating agents. Health Phys. 1982;42:520–5.
Miller SC, Bruenger FW, Kuswik-Rabiega G, Lloyd RD. Decorporation of plutonium by oral administration of a partially lipophilic polyaminocarboxylic acid. Health Phys. 1992;63:195–7.
Miller SC, Bruenger FW, Kuswik-Rabiega G, Lloyd RD. Duration and Dose-related effects of an orally administered, partially lipophilic polyaminocarboxylic acid on the decorporation of plutonium and americium. J Pharmacol Exp Ther. 1993;267:548–54.
Bruenger FW, Kuswik-Rabiega G, Miller SC. Decorporation of aged americium deposits by oral administration of lipophilic polyamino carboxylic acids. J Med Chem. 1992;35:112–8.
Miller SC, Wang X, Bowman BM. Pharmacological properties of orally available, amphipathic polyaminocarboxylic acid chelators for actinide decorporation. Health Phys. 2010;99:408–12.
Sueda K, Sadgrove MP, Huckle JE, Leed MG, Weber WM, Doyle-Eisele M, Guilmette RA, Jay M. Orally administered DTPA penta-ethyl ester for the decorporation of inhaled (241). Am J Pharm Sci. 2014;103:1563–71.
Kirk JF, Abernethy JA, Tomisaka DM, Talton JD. Preclinical toxicology, pharmacology, and efficacy of a novel orally administered diethylenetriaminepentaacetic acid (DTPA) formulation. Drug Dev Res. 2012;73:232–42.
Wilson JP, Cobb RR, Dungan NW, Matthews LL, Eppler B, Aiello KV, Curtis S, Boger T, Guilmette RA, Weber W, Doyle-Eisele M, Talton JD. Decorporation of systemically distributed americium by a novel orally administered diethylenetriaminepentaacetic acid (DTPA) formulation in beagle dogs. Health Phys. 2015;108:308–18.
Peters R, Stocken L, Thompson R. British anti-lewisite (BAL). Nature. 1945;156:616–9.
Hoover TD, Aposhian HV. BAL increases the arsenic-74 content of rabbit brain. Toxicol Appl Pharmacol. 1983;70:160–2.
Berlin M, Ullberg S. Increasing uptake of mercury in mouse brain caused by 2,3-dimercaptopropanol (BAL). Nature. 1963;197:84–5.
Andersen O. Chemical and biological considerations in the treatment of metal intoxications by chelating agents. Mini Rev Med Chem. 2004;4:11–21.
Englund GS, Dahlqvistt R, Lindelof B, Soderman E, Jonzon B, Vesterberg O, Larsson KS. DMSA administration to patients with alleged mercury poisoning from dental amalgams: a placebo-controlled study. J Dent Res. 1994;73:620–8.
Alan L, Miller ND. Dimercaptosuccinic acid (DMSA), a non-toxic, water-soluble treatment for heavy metal toxicity. Altern Med Rev. 1998;3:199–207.
Graziano JH. Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med Tox. 1986;1:155–62.
Flora SJS, Dubey R, Kannan GM, Chauhan RS, Pant BP, Jaiswal DK. Meso-2,3-dimercaptosuccinic acid (DMSA) and monoisoamyl DMSA effect on gallium arsenide induced pathological liver injury in rats. Toxicol Lett. 2002;132:9–17.
Flora SJS, Pande M, Kannan GM, Mehta A. Lead induced oxidative stress and its recovery following co-administration of melatonin or n-acetylcysteine during chelation with succimer in male rats. Cell Mol Biol. 2004;50:543–51.
Jones MM, Singh PK, Gale GR, Smith AB, Atkins LM. Cadmium mobilization in vivo by intraperitoneal or oral administration of mono alkyl esters of meso-2,3-dimercaptosuccinic acid. Pharmacol Toxicol. 1992;70:336–43.
Kreppel H, Reichl F-X, Szinicz L, Fichtl B, Forth W. Efficacy of various dithiol compounds in acute As2O3 poisoning in mice. Arch Toxicol. 1990;64:387–92.
Aposhian HV, Maiorino RM, Dart RC, Perry DF. Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects. Clin Pharmacol Ther. 1989;45:520–6.
Gersl V, Hrdina R, Vavrova J, Holeckova M, Palicka V, Vogkova J, Mazurova Y, Bajgar J. Effects of repeated administration of dithiol chelating agent- sodium 2,3-dimercapto 1-propanesulphonate (DMPS)- on biochemical and hematological parameters in rabbits. Acta Med Austriaca. 1997;40:3–8.
Flora SJS, Bhattacharya R, Vijayaraghavan R. Combined therapeutic potential of meso 2,3-dimercaptosuccinic acid and calcium disodium edetate in the mobilization and distribution of lead in experimental lead intoxication in rats. Fund Appl Toxicol. 1995;25:233–40.
Kalia K, Flora SJS. Strategies for safe and effective treatment for chronic arsenic and lead poisoning. J Occup Hlth. 2005;47:1–21.
Aposhian MM, Maiorino RM, Xu Z. Sodium 2,3-dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rats. Toxicology. 1996;109:49–55.
Yamada R. Antivitamin B6 activity of L-penicillamine in Escherichia coli. Acta Vitaminol Enzymol. 1983;5:73–81.
Roussaeux CG, MacNabb LG. Oral administration of D-penicillamine causes neonatal mortality without morphological defects in CD-1 mice. J Appl Toxicol. 1992;12:35–8.
Peisach J, Blumberg WE. A mechanism for the action of penicillamine in the treatment of Wilson's disease. Mol Pharmacol. 1969;5:200–9.
Crisponi G, Nurchi VM, Fanni D, Gerosa C, Nemolato S, Faa G. Copper- related diseases: from chemistry to molecular pathology. Coord Chem Rev. 2010;254:876–89.
Gupta B, Srivastava RK, Saxena KK, Prasad DN. A study on the penicillamine induced gastric ulceration in the rat. Ind J Pharmacol. 1980;12:247–52.
Grasedyck K. D-penicillamine—side effects, pathogenesis and decreasing the risks. Z Rheumatol. 1988;47:17–9.
Kodama H, Meguro Y, Tsunakawa A, Nakazato Y, Abe T, Murakita H. Fate of orally administered triethylenetetramine dihydrochloride: a therapeutic drug for Wilson’s disease. Tohoku J Exp Med. 1993;169:59–66.
Kodama H, Murata Y, Iitsuka T, Abe T. Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci. 1997;61:899–907.
Suzuki KT, Ogra Y. Formation of copper-metallothionein/tetrathiomolybdate complex is the first step in removal of cu from LEC rats. Res Commun Mol Pathol Pharmacol. 1995;88:187–95.
Ogra Y, Chikusa H, Suzuki KT. Metabolic fate of the insoluble copper/tetrathiomolybdate complex formed in the liver of LEC rats with excess tetrathiomolybdate. J Inorg Biochem. 2000;78:123–8.
Harper PL, Walshe JM. Reversible pancytopenia secondary to treatment with Tetrathiomolybdate. Br J Haematol. 1986;64:851–3.
Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J. Treatment of Wilson disease with ammonium tetrathiomolybdate. IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006;63:521–7.
Brewer GJ. The modern treatment of Wilson’s disease. J Gastrointest Dig Syst. 2015;5:1–9.
Bahnemann R, Leibold E, Kittel B, Mellert W, Jackh R. Different patterns of kidney toxicity after sub-acute administration of Na-nitrilotriacetic acid and Fe-nitrilotriacetic acid to Wistar rats. Toxicol Sci. 1998;46:166–75.
Tandon SK, Mathur AK. Chelation in metal intoxication. III. Lowering of nickel content in poisoned rat organs. Acta Pharmacol Toxicol. 1976;38:401–8.
Dietrich DR, Swenberg JA. Preneoplastic lesions in rodent kidney induced spontaneously or by non-genotoxic agents: predictive nature and comparison to lesion induced by genotoxic carcinogens. Mutat Res. 1991;248:239–60.
Anderson RL. The role of zinc in nitrilotriacetate (NTA)-associated renal tubular cell toxicity. Fd Cosmet Toxicol. 1981;19:639–50.
Hartwig A, Klyszcz-Nasko H, Schlepegrell R, Beyersmann D. Cellular damage by ferric nitrilotriacetate and ferric citrate in V79 cells: interrelationship between lipid peroxidation, DNA strand breaks and sister chromatid exchange. Carcinogenesis. 1993;14:107–12.
Umemura T, Hasegawa R, Sai-Kato K, Nishikawa A, Furukawa F, Toyokum S, Uchida K, Inouc T, Kurokawa Y. Prevention by 2-mercaptoethane sulfonate and N-acetylcysteine of renal oxidative damage in rats treated with ferric nitrilotriacetate. Jpn J Cancer Res. 1996;87:882–6.
Hershko C, Link G, Tzahor M, Pinson A. In: Bergeron RJ, Brittenham GM, editors. The development of iron Chelators for clinical use. Boca Raton, FL: CRC Press; 1994. p. 75–96.
Moeschlin S, Schnider U. Treatment of primary and secondary hemochromatosis and acute iron poisoning with a new, potent iron-eliminating agent, desferrioxamine B. New Engl J Med. 1963;269:57–66.
Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos. 1993;21:640–4.
Pippard MJ. In: Bergeron RJ, Brittenham GM, editors. The development of iron Chelators for clinical use. Boca Raton, FL: CRC Press; 1994. p. 57–74.
Faa G, Crisponi G. Iron chelating agents in clinical practice. Coord Chem Rev. 1999;184:291–310.
Hider RC, Kontoghiorghes GJ, Silver J. UK Patent GB-2118176, 1982.
Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79:2741–8.
Kontoghiorghes GJ. Iron mobilization from ferritin using α-oxohydroxy heteroaromatic chelators. Biochem J. 1986;233:299–302.
Kontoghiorghes GJ. The study of iron mobilisation from transferrin using α- ketohydroxy heteroaromatic chelators. Biochim Biophys Acta. 1986;869:141–6.
Hider RC, Porter JB, Singh S. In: Bergeron RJ, Brittenham GM, editors. The development of iron Chelators for clinical use. Boca Raton, FL: CRC Press; 1994. p. 354–71.
Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, Louis PS, Freedman MH, McClelland RA, Templeton DM. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 1990;336:1275–9.
Capellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade®). Best Prac & Res Clin Haemat. 2005;18:289–98.
Department of Health and Human Services, Food and Drug Administration, Guidance for industry on Prussian Blue for treatment of internal contamination with Thallium or radioactive Cesium; Availability. Docket No. 03D-0023, 2003.
Pearce J. Studies of any toxicological effects of Prussian blue compounds in mammals—a review. Food Chem Toxicol. 1994;32:577–82.
Bergeron RJ, Wiegand J, Singh S. Desferrithiocin analogue uranium decorporation agents. Int J Radiat Biol. 2009;85:348–61.
Metivier H, Masse R, Durbin PW, Raymond KN. Promotion by tetrameric catechoylamide ligands and CaNa3-DTPA of the dissociation in vitro of the Putransferrin complex formed after intravenous injection of Pu-tri-N-butylphosphate. Health Phys. 1985;49:1302–5.
Lloyd RD, Bruenger FW, Mays CW, Atherton DR, Jones CW, Taylor GN, Stevens W, Durbin PW, Jeung N, Jones ES, et al. Removal of Pu and am from beagles and mice by 3,4,3-LICAM(C) or 3,4,3-LICAM(S). Radiat Res. 1984;99:106–28.
Duffield JR, Taylor DM, Proctor SA. The binding of plutonium to transferrin in the presence of tri-n-butyl phosphate or nitrate and its release by diethylenetriaminepenta-acetate and the tetrameric catechoylamide ligand LICAMC(C). Int J Nucl Med Biol. 1986;12:483–7.
Volf V, Wirth R. Effective chelation therapy after incorporation of neptunium-239 in rats. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;50:955–9.
Durbin PW, Jeung N, Jones ES, Weitl FL, Raymond KN. Specific sequestering agents for the actinides: 10. Enhancement of 238Pu elimination from mice by poly(catechoylamide) ligands. Radiat Res. 1984;99:85–105.
Volf V. Chelation therapy of incorporated plutonium-238 and americium-241: comparison of LICAM(C), DTPA and DFOA in rats, hamsters and mice. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;49:449–62.
Guseva Canu I, Jacob S, Cardis E, Wild P, Caer S, Auriol B, Garsi JP, Tirmarche M, Laurier D. Uranium carcinogenicity in humans might depend on the physical and chemical nature of uranium and its isotopic composition: results from pilot epidemiological study of French nuclear workers. Cancer Causes Control. 2011;22:1563–73.
Durbin PW, Lauriston S. Taylor lecture: the quest for therapeutic actinide chelators. Health Phys. 2008;95:465–92.
Ramounet-Le Gall B, Grillon G, Rateau G, Burgada R, Bailly T, Fritsch P. Comparative decorporation efficacy of 3,4,3-LIHOPO, 4,4,4-LIHOPO and DTPA after contamination of rats with soluble forms of 238Pu and 233U. Radiat Prot Dosim. 2003;105:535–8.
Abergel RJ, Durbin PW, Kullgren B, Ebbe SN, Xu J, Chang PY, Bunin DI, Blakely EA, Bjornstad KA, Rosen CJ, Shuh DK, Raymond KN. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Phys. 2010;99:401–7.
Guilmette RA, Hakimi R, Durbin PW, Xu J, Raymond KN. Competitive binding of Pu and Am with bone mineral and novel chelating agents. Radiat Prot Dosim. 2003;105:527–34.
Henge-Napoli MH, Archimbaud M, Ansoborlo E, Metivier H, Gourmelon P. Efficacy of 3,4,3-LIHOPO for reducing the retention of uranium in rat after acute administration. Int J Radiat Biol. 1995;68:389–93.
An DD, Villalobos JA, Morales-Rivera JA, Rosen CJ, Bjornstad KA, Gauny SS, Choi TA, Sturzbecher-Hoehne M, Abergel RJ. (238)Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice. Int J Radiat Biol. 2014;90:1055–61.
Durbin PW, Kullgren B, Xu J, Raymond KN, Henge-Napoli MH, Bailly T, Burgada R. Octadentate hydroxypyridinonate (HOPO) ligands for plutonium (i.v.): pharmacokinetics and oral efficacy. Radiat Prot Dosim. 2003;105:503–8.
Bunin DI, Chang PY, Doppalapudi RS, Riccio ES, An D, Jarvis EE, Kullgren B, Abergel RJ. Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen. Radiat Res. 2013;179:171–82.
Choi TA, Furimsky AM, Swezey R, Bunin DI, Byrge P, Iyer LV, Chang PY, Abergel RJ. In vitro metabolism and stability of the actinide chelating agent 3,4,3-LI(1,2-HOPO). J Pharm Sci. 2015;104:1832–8.
Fattal E, Tsapis N, Phan Elias G. Novel drug delivery systems for actinides (uranium and plutonium) decontamination agents. Adv Drug Deliv Rev. 2015;90:40–54.
Henge-Napoli MH, Ansoborlo E, Chazel V, Houpert P, Paquet F, Gourmelon P. Efficacy of ethane-1-hydroxy-1,1-bisphosphonate (EHBP) for the decorporation of uranium after intramuscular contamination in rats. Int J Radiat Biol. 1999;75:1473–7.
Ubios AM, Braun EM, Cabrini RL. Lethality due to uranium poisoning is prevented by ethane-1-hydroxy-1,1-biphosphonate (EHBP). Health Phys. 1994;66:540–4.
Martinez AB, Cabrini RL, Ubios AM. Orally administered ethane-1-hydroxy-1,1- biphosphonate reduces the lethal effect of oral uranium poisoning. Health Phys. 2000;78:668–71.
Martinez AB, Mandalunis PM, Bozal CB, Cabrini RL, Ubios AM. Renal function in mice poisoned with oral uranium and treated with ethane-1-hydroxy-1,1- bisphosphonate (EHBP). Health Phys. 2003;85:343–7.
Fukuda S, Iida H, Ikeda M, Yan X, Xie Y. Toxicity of uranium and the removal effects of CBMIDA and EHBP in simulated wounds of rats. Health Phys. 2005;89:81–8.
Bozal CB, Martinez AB, Cabrini RL, Ubios AM. Effect of ethane-1-hydroxy-1,1-bisphosphonate (EHBP) on endochondral ossification lesions induced by a lethal oral dose of uranyl nitrate. Arch Toxicol. 2005;79:475–81.
Tymen H, Gerasimo P, Hoffschir D. Contamination and decontamination of rat and human skin with plutonium and uranium, studied with a Franz's chamber. Int J Radiat Biol. 2000;76:1417–24.
Giglio MJ, Frid A, Bozzini CE. Influence of bisphosphonate on the negative Erythropoietic effects of uranyl nitrate. Int J Clin Lab Res. 1997;27:199–201.
Houpert P, Chazel V, Paquet F, Bailly T, Burgada R, Henge-Napoli MH. Reduction of uranium transfer by local chelation in simulated wounds in rats. Hum Exp Toxicol. 2001;20:237–41.
Houpert P, Chazel V, Paquet F. A local approach to reduce industrial uranium wound contamination in rats. Can J Physiol Pharmacol. 2004;82:73–8.
Sawicki M, Lecerclé D, Grillon G, Le Gall B, Sérandour A-L, Poncy J-L, Bailly T, Burgada R, Lecouvey M, Challeix V, Leydier A, Pellet-Rostaing S, Ansoborlo E, Taran F. Bisphosphonate sequestering agents. Synthesis and preliminary evaluation for in vitro and in vivo uranium(VI) chelation. Eur J Med Chem. 2008;43:2768–77.
Bouvier-Capely C, Manoury A, Legrand A, Bonthonneau JP, Cuenot F, Rebière F. The use of calix[6]arene molecules for actinides analysis in urine and drinking water: an alternative to current procedures. J Radioanal Nucl Chem. 2009;282:611–5.
Dinse C, Baglan N, Cossonnet C, Bouvier C. New purification protocol for actinide measurement in excreta based on calixarene chemistry. Appl Radiat Isot. 2000;53:381–6.
Petrella AJ, Raston CL. Calixarenes as platforms for the construction of multimetallic complexes. J Organomet Chem. 2004;689:4125–36.
Araki K, Hashimoto N, Otsuka H, Nagasaki T, Shinkai S. Molecular design of a calix[6] arene-based super-uranophile with C3 symmetry. High UO2 2+ selectivity in solvent extraction. Chem Lett. 1993;22:829–32.
Rodik RV, Boyko VI, Kalchenko VI. Calixarenes in bio-medical researches. Curr Med Chem. 2009;16:1630–55.
Da Silva E, Shahgaldian P, Coleman AW. Haemolytic properties of some water soluble para-sulphonato-calix-[n]-arenes. Int J Pharm. 2004;273:57–62.
Yantasee W, Rutledge RD, Chouyyok W, Sukwarotwat V, Orr G, Warner CL, Warner MG, Fryxell GE, Wiacek RJ, Timchalk C, Addleman RS. Functionalized Nanoporous silica for the removal of heavy metals from biological systems: adsorption and application. ACS Appl Mater Interfaces. 2010;2:2749–58.
Sangvanich T, Morry J, Fox C, Ngamcherdtrakul W, Goodyear S, Castro D, Fryxell GE, Addleman RS, Summers AO, Yantasee W. Novel oral detoxification of mercury, cadmium, and lead with thiol-modified nanoporous silica. ACS Appl Mater Interfaces. 2014;6:5483–93.
Sangvanich T, Ngamcherdtrakul W, Lee R, Morry J, Castro D, Fryxell GE, Yantasee W. Nanoporous sorbent material as an oral phosphate binder and for aqueous phosphate, chromate, and arsenate removal. J Nanomed Nanotechnol. 2014;5:4.
Prystowsky SD, Allen AM, Smith RW, Nonomura JH, Odom RB, Akers WA. Allergic contact hypersensitivity to nickel neomycin ethylenediamine and benzocaine. Arch Dermatoll. 1979;115:959–62.
Fischer T. In: Maibach HI, Menne T, editors. Nickel and the skin; immunology and toxicology. Boca Raton, FL: CRC Press; 1989. p. 117–32.
Orchard S. Barrier creams. Dermatol C/in. 1984;2:619–29.
Hepburn I. Personal communication. UK: Royal Mint; 1993.
Memon AA, Molokhia MM, Friedmann PS. The inhibitory effects of topical chelating agents and antioxidants on nickel-induced hypersensitivity reactions. J Am Acad Dermatol. 1994;30:560–5.
Allenby CF, Goodwin BFJ. Influence of detergent washing powders on minimal eliciting patch test concentrations of nickel and chromium. Contact Dermatitis. 1983;9:491–9.
Resl V, Sykora J. In vitro testing of ointments designed to protect the skin from damage by chromium and nickel. Dermatol Wochenschr. 1965;151:1327–40.
Kurtin A, Orentreich N. Chelation deactivation of nickel ion in allergic eczematous sensitivity. J Invest Dermatol. 1954;22:441–5.
Gawkrodger DJ, Healy J, Howe AM. The prevention of nickel contact dermatitis- a review of the use of binding agents and barrier creams. Contact Dermatitis. 1995;32:257–65.
Whorl S, Kriechbaumer N, Hemmer W, Focke M, Brannath W, Gotz M, Jarisch R. A cream containing the chelator DTPA (diethylenetriaminepenta-acetic acid) can prevent contact allergic reactions to metals. Contact Dermatitis. 2001;44:224–8.
Berndt U, Wigger-Alberti W, Gabard B, Elsner P. Efficacy of a barrier cream and its vehicle as protective measures against occupational irritant contact dermatitis. Contact Dermatitis. 2000;42:77–80.
Jarisch R, Ballczo H, Richter W. Nickel allergy—elimination of the harmful agent with cation exchangers (I). Z Hautkr. 1975;50:33–9.
Jarisch R, Ballczo H, Richter W. Nickel allergy—elimination of the harmful agent with cation exchangers (II). Z Hautkr. 1975;50:53–7.
Vemula PK, Rox Anderson R, Karp JM. Nanoparticles reduce nickel allergy by capturing metal ions. Nat Nanotech. 2011;6:291–5.
Disclosure
J.M.K., P.K.V, and E.B. hold equity in Skintifique, a company that has developed a proprietary nickel chelation technology and is commercializing products derived from this technology. E.B. is also an employee of Skintifique. J.M.K. and P.K.V. may benefit financially from Skintifique commercial sales of these products if the corresponding IP is licensed or optioned. The interests of J.M.K. and P.K.V. were reviewed and are subjected to a management plan overseen by their institutions in accordance with their conflict of interest policies.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Mahato, M. et al. (2018). Prevention of Metal Exposure: Chelating Agents and Barrier Creams. In: Chen, J., Thyssen, J. (eds) Metal Allergy. Springer, Cham. https://doi.org/10.1007/978-3-319-58503-1_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-58503-1_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-58502-4
Online ISBN: 978-3-319-58503-1
eBook Packages: MedicineMedicine (R0)